Register Education Students Posters Resources Engage Destination Supporters #BeThe1To

CPNP 2019 industry supported symposia are scientific programs developed for educational purposes. All symposia at CPNP 2019 are designed for the psychiatric pharmacist and are included in participant registration fees. All symposia are in compliance with Accreditation Council for Pharmacy Education (ACPE) criteria for planning and implementation and provide 1.5 contact hours of ACPE credit. Meals or snack items may be provided at the start of each event. Room capacities at symposia are limited and entrance is granted on a first-come, first-served basis.

Sunday, April 7, 11:30 a.m.-1:15 p.m. (Lunch Provided)

Emerging Mechanisms and Treatments for Depression

Our understanding of the neurobiology of depression has drastically expanded in recent years, and there is increasing recognition that the neurobiological substrates of depression go beyond the monoaminergic circuits. The frequency of treatment-resistance to first-line anti-depressants has spurred research into novel molecular targets and neural circuits for depression, as well as the development of an array of novel anti-depressants that act outside the traditional monoaminergic circuitry. Glutamatergic neurotransmission, along with modulation of the reward system via opioid receptors and beta endorphins, in fact all appear to play a key role in the pathophysiology of depression. 
 
In this presentation, Dr. Patrick Finley and Dr. Leslie Citrome will provide an update on novel antidepressant treatments that are recently available or in development, including the mechanisms of action that are thought to underlie their potential antidepressant effects.
 
Presentation will include discussion of off-label, experimental, and/or investigational use of drugs or devices: ketamine; esketamine; psilocybin; d-cycloserine; rapastinel; SAGE-547 (brexanolone); SAGE-217; ALKS 5461 (buprenorphine + samidorphan); deep transcranial magnetic stimulation (DTMS); repetitive transcranial magnetic stimulation (rTMS); synchronized transcranial magnetic stimulation (sTMS); low field magnetic stimulation (LFMS); scopolamine; onabotulinumtoxin A; mifepriston; metyrapone; org-34517; AXS 05 (dextro-methorphan + bupropion); nitrous oxide

Faculty

Patrick Finley, PharmD, BCPP
Professor of Clinical Pharmacy
University of California
San Francisco, CA
 
No relevant financial relationships to disclose.
 
Leslie Citrome, MD, MPH
Clinical Professor of Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, NY
 
Disclosures
 
Consultant: Acadia, Alkermes, Allergan, Indivior, Intra-Cellular Therapeutics, Janssen, Lundbeck, Merck, Neurocrine, Noven, Osmotica, Otsuka, Pfizer, Shire, Sunovion, Takeda, Teva, Vanda 
Speaker's Bureau: Acadia, Alkermes, Allergan, Janssen, Lundbeck, Merck, Neurocrine, Otsuka, Pfizer, Shire, Sunovion, Takeda, Teva
Financial, Major Stockholder: Stocks (small number of shares of common stock): Bristol-Myers Squibb, Eli Lilly, J & J, Merck, Pfizer purchased > 10 years ago
Financial, Royalties: Wiley (Editor-in-Chief, International Journal of Clinical Practice), UpToDate (reviewer), Springer Healthcare (book)

Learning Objectives

  1. Explain the potential utility of antidepressant agents that act outside of serotonergic neurotransmission
  2. Explore the mechanisms of action and efficacy of novel antidepressants

Agenda and Requirements for Successful Completion

  • Welcome and Introductions; Pre-Test
  • Beyond Monoamines: The Neurobiology of Depression
  • What's the Status? Development and Approval of Novel Anti-Depressants
  • Case Presentations
  • Post-Test; Q&A

Continuing Education

ACPEThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This course provides 1.5 contact hours of knowledge-based continuing education credit from CPNP approved programming. The ACPE number is 0284-9999-19-060-L01-P.

Offered by

Neuroscience Education Institute

Supported by

Alkermes

Tuesday, April 9, 6:45-8:30 a.m. (Breakfast Provided)

Changing the Treatment Landscape: Embracing Long-Acting Injectable Antipsychotics

This interactive educational session will provide a comprehensive update on long-acting injectable (LAI) antipsychotic agents and their role in the treatment of schizophrenia. In recent years, the landscape has changed with the increasing use of LAIs as new data tout benefits of these agents over oral treatment in many clinical situations. Recent evidence suggests that LAIs may improve adherence, reduce relapse and hospitalizations, lessen the risk of treatment failure, and decrease mortality. Evidence also suggests the use of these treatments should be offered at an earlier place in illness. Newly FDA-approved long-acting injectable antipsychotic agents may be dosed without oral overlap, paving the way to less burdensome initiation strategies.
 
This presentation will explore how the psychiatric pharmacist can play an important role in advocating for earlier introduction of LAIs in schizophrenia, evidence-based approaches to LAI selection, and how best to initiate agents and manage maintenance dosing to improve treatment outcomes.

Faculty

Deanna Kelly, PharmD, BCPP; CPNP Member Activity Chair
Professor
University of Maryland
Baltimore, MD

Leslie Citrome, MD, MPH
Clinical Professor of Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, NY
 
Megan J. Ehret, PharmD, MS, BCPP
Associate Professor
University of Maryland
Baltimore, MD

Learning Objectives

  1. Review the evidence base of long-acting injectable antipsychotics (LAI) with regard to hospitalization and relapse.
  2. Identify the role of LAIs in the treatment continuum and discuss their use earlier in the schizophrenia disease course.
  3. Compare LAIs with regard to initiation and maintenance dosing.
  4. Incorporate LAIs into treatment regimens using case-based examples.

Agenda

  • Welcome and Introductions, Pre-test
  • An Era of Change of Long Acting Injectable Antipsychotics: Embracing New Evidence and Data
  • Deciding Among the Selections: What are the Pros and Cons of the Available LAIs?
  • Case Presentations
  • Post-test; Audience Q&A with Faculty

Continuing Education

In support of improving patient care, Creative Educational Concepts, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Pharmacy (ACPE)

This application-based activity is approved for 1.5 contact hours (0.15 CEUs) of continuing pharmacy education credit. Pharmacy credit will be reported directly to the National Association of Boards of Pharmacy (NABP) CPE Monitor electronic CE tracking system.

Offered by

Creative Educational Concepts, Inc.

Supported by

Indivior, Alkermes

Tuesday, April 9, 12:00-1:45 p.m. (Lunch Provided)

Practical Strategies for Patient Follow-Up and Long-Term VMAT2 Inhibitor Treatment

An estimated 20% of patients taking an antipsychotic medication will develop the iatrogenic disorder tardive dyskinesia (TD), marked by abnormal involuntary movements and imposing a substantial negative impact on patient quality of life and clinical outcomes. In 2017, the first pharmacotherapies for the treatment of TD—the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine—were approved, rendering routine diagnosis and monitoring of TD more essential than ever in order to support timely and effective treatment with these agents. In this session, expert faculty will review clinical trial data surrounding long-term efficacy and tolerability of VMAT2 inhibitors as well as discuss steps to take to ensure patients have access to this important medication.

Faculty

Stephen Saklad, PharmD, BCPP (Chair)
Clinical Professor and Director of Psychiatric Pharmacy Program
The University of Texas at Austin, College of Pharmacy, Pharmacotherapy Division
San Antonio, TX

Leslie Citrome, MD, MPH
Clinical Professor of Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, NY

Learning Objectives

  1. Evaluate the available clinical trial data surrounding the long-term efficacy and tolerability of VMAT2 inhibitors for the treatment of TD
  2. Outline the discrete dosing schedules and patient population-specific treatment considerations of available VMAT2 inhibitors for the treatment of TD
  3. Engage in available patient support programs and communication practices that facilitate VMAT2 inhibitor access through the specialty pharmacy and subsequent treatment continuation

Agenda

  • Pre-Activity Survey
  • Interactive, Case-Based, Expert Presentation
    • Journal Club Discussion: Long-Term Efficacy and Safety of VMAT2 Inhibitors
    • Challenges in Long-Term TD Management: Patient Follow-Up Videos and Discussion
    • Discussion and Q&A
  • Post-Activity Survey & Evaluation

Offered by

North American Center for Continuing Education (NACCME)

Supported by

Educational grants from Neurocrine Biosciences and Teva Pharmaceuticals